Clinical Trial Update: Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of erlotinib and celecoxib with reirradiation in recurrent head and neck cancer; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Laryngeal Cancer
• Paranasal Sinus Cancer
• Pharyngeal Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Johnny Kao | Conditions: Cancer of the Pharynx, Cancer of the Larynx | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-04-10